Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04054986 · ClinicalTrials.gov registry record · Phase 1
Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04054986: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04054986 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04054986, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.
Primary Outcome
The safety of patients will be evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1 and grade 2 toxicities are considered safe.
Interventions
- OTHER Blood draw
- DIAGNOSTIC_TEST F-Var3 PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-08-09 |
| Est. Completion | 2020-09-18 |
| Phase | Phase 1 |
What the finished NCT04054986 record still lists
NCT04054986 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Blood draw is the first listed.
NCT04054986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04054986 about?
NCT04054986 is a clinical study titled "Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer". The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.
What is the current status of trial NCT04054986?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-08-09. Estimated completion is 2020-09-18.
What interventions are being tested in trial NCT04054986?
The interventions under investigation include: Blood draw (OTHER), F-Var3 PET/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04054986?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04054986's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI